Radiopharm Theranostics, a company dedicated to advancing radiopharmaceutical and nuclear medicine, has secured $8.8M in new funding. The capital will support its mission to develop a world-class platform of products designed for both diagnostic and therapeutic uses.
This investment underscores the ongoing development in specialized medical technologies, as Radiopharm Theranostics continues to build out its pipeline of precision tools. The company's work focuses on creating innovative solutions that can both identify and treat a range of conditions, leveraging the power of radiopharmaceuticals.
%20Sdn%20Bhd.png&w=3840&q=75)
